[1] Marso S P, Daniels G H, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4):311-322.
[2] Marso S P, Bain S C, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016,375(19):1834-1844.
[3] Gerstein H C, Colhoun H M, Dagenais G R, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND)[J]. Lancet, 2019,394(10193):121-130.
[4] Holman R R, Bethel M A, Mentz R J, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2017,377(13):1228-1239.
[5] Hernandez A F, Green J B, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease(HARMONY Outcomes):a double-blind, randomised placebo-controlled trial[J]. Lancet, 2018,392(10157):1519-1529.
[6] Gerstein H C, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes[J]. N Engl J Med, 2021, 385(10):896-907.
[7] Husain M, Birkenfeld A L, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2019, 381(9):841-851.
[8] Lincoff A M, Brown-Frandsen K, Colhoun H M, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes[J]. N Engl J Med, 2023, 389(24):2221-2232.
[9] Drucker D J. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27(4):740-756.
[10] Hamed K, Alosaimi M N, Ali B A, et al. Glucagon-Like Peptide-1(GLP-1)Receptor agonists:exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review[J]. Cureus, 2024, 16(9):e68390.
[11] Nauck M A, Quast D R, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J]. Mol Metab, 2021, 46:101102.
[12] Yang H M. GLP-1 Agonists in Cardiovascular Diseases:Mechanisms, Clinical Evidence, and Emerging Therapies[J]. J Clin Med, 2025, 14(19):6758.
[13] Management of Hyperglycemia in type 2 Diabetes, 2022. A consensus report by the American Diabetes Association(ADA)and the European Association for the study of diabetes(EASD)[J]. Diabetes Care, 2022, 45(11):2753-2786.
[14] Cersosimo A, Salerno N, Sabatino J, et al. Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra:insights from cardiovascular magnetic resonance[J]. Cardiovasc Diabetol, 2024, 23(1):94.
[15] Ripa R S, Zobel E H, von Scholten B J, et al. Effect of Liraglutide on arterial inflammation assessed as [18F]FDG uptake in patients with type 2 diabetes:a randomized, double-blind, placebo-controlled trial[J]. Circ Cardiovasc Imaging, 2021, 14(7):e012174.
[16] Helmstädter J, Frenis K, Filippou K, et al. Endothelial GLP-1(Glucagon-Like Peptide-1)receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension[J]. Arterioscler Thromb Vasc Biol, 2020, 40(1):145-158.
[17] Williams M C, Kwiecinski J, Doris M, et al. Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction:results from the multicenter SCOT-HEART trial(scottish computed tomography of the HEART)[J]. Circulation, 2020, 141 (18): 1452-1462.
[18] Narula J, Chandrashekhar Y, Ahmadi A, et al. SCCT 2021 Expert Consensus Document on coronary computed tomographic angiography:a report of the Society of Cardiovascular Computed Tomography[J]. J Cardiovasc Comput Tomogr, 2021, 15(3):192-217.
[19] Wei R, Ma S, Wang C, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner[J]. Am J Physiol Endocrinol Metab, 2016, 310(11):E947-957.
[20] Tarkin J M, Joshi F R, Rudd J H F. PET imaging of inflammation in atherosclerosis[J]. Nat Rev Cardiol, 2014, 11(8):443-457.
[21] Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes[J]. Circulation, 2022, 146(24):1882-1894.
[22] Park B, Ussher J R. GLP-1 receptor agonists and atherosclerosis protection:the vascular endothelium takes center stage[J]. Am J Physiol Heart Circ Physiol, 2024, 326(5):H1159-H1176.
[23] Kosiborod M N, Abildstrøm S, Borlaug B, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity[J]. N Engl J Med, 2023, 389(12):1069-1084.
[24] Kosiborod M N, Petrie M C, Borlaug B A, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes[J]. N Engl J Med, 2024, 390(15):1394-1407.
[25] Perkovic V, Tuttle K R, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391(2):109-121.
[26] Mann J F E, Ørsted D D, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes[J]. N Engl J Med, 2017, 377(9):839-848.
[27] Sunil V B, Anika B, Matthew M Y Lee, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes:a meta-analysis of randomised controlled trials[J]. Lancet Diabetes Endocrinol, 2025, 13(1):15-28.
[28] Pfeffer M A, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med, 2015,373(23):2247-2257.
[29] Kristensen S, Rørth R, Jhund P S, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10):776-785.
[30] Tuttle K R, Bosch-Traberg H, Cherney D Z I, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo[J]. Kidney Int, 2023, 103(4):772-781.
[31] Brendon L N, Robert A F, Lauren H,et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes:a systematic review and meta-analysis[J]. Circulation, 2024, 150(22):1781-1790.
[32] Deanfield J, Verma S, Scirica B M,et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure:a prespecified analysis of the SELECT trial[J]. Lancet, 2024, 404:773-786.
[33] American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment:standards of care in diabetes-2025[J]. Diabetes Care, 2025, 48(Suppl 1):S181-S206.
[34] Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J, 2023, 44(39):4043-4140.
[35] Tuttle K R, Brosius F C, Cavender M A,et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes:report of a scientific workshop sponsored by the National Kidney Foundation[J]. Am J Kidney Dis, 2021, 77(1):94-109.